Insulin Aspart

1
Insulin Aspart
Brands

DEA Class; Rx

Common Brand Names; NovoLog, NovoLog FlexPen, NovoPen Echo, NovoLog FlexTouch, Fiasp

  • Antidiabetics, Insulins; 
  • Antidiabetics, Rapid-Acting Insulins

Rapid-acting insulin analog; quicker onset/shorter duration of action than regular insulin
Used in adult and pediatric patients with type 1 and 2 diabetes mellitus; often used as prandial insulin
Faster-acting insulin aspart (Fiasp) has a different onset of action and timing of administration with respect to meals

Indicated for the treatment of type 1 diabetes mellitus, Improvement of glycemic control in adults and children with diabetes mellitus.

For the treatment of type 2 diabetes mellitus, Diabetes inadequately controlled by diet, weight reduction, exercise, or oral medication.
For the treatment of gestational diabetes or for the treatment of patients with pre-existing diabetes mellitus (type 1 or type 2) who are now pregnant.
For the treatment of diabetic ketoacidosis (DKA).

During episodes of hypoglycemia

Documented hypersensitivity

Nasopharyngitis, postmeal Fiasp with insulin detemir (23.9%)

Nasopharyngitis, mealtime Fiasp with insulin detemir (20.2%)

Fiasp with insulin glargine

  • Urinary tract infection (5.9%)

  • Severe hypoglycemia (3.2%)

Mealtime Fiasp with insulin detemir

  • Upper respiratory tract infection (9.1%)

  • Severe hypoglycemia (6.7%)

  • Diarrhea (5.4%)

  • Back pain (5.2%)

  • Nausea (4.9%)

Post meal Fiasp with insulin detemir

  • Severe hypoglycemia (8%)

  • Upper respiratory tract infection (7.4%)

  • Diarrhea (5%)

  • Back pain (4%)

  • Nausea (3.2%)

Novolog

  • Hypoglycemia

  • Lipodystrophy

  • Lipohypertrophy

  • Local allergic reaction

  • Hypokalemia

  • Paresthesia

  • Itching

  • Tremor

  • Hunger

  • Nausea

  • Urticaria

  • Redness

  • Diaphoresis

  • Hypothermia

  • Mental confusion

Fiasp with insulin aspart

  • Hyperglycemia (with repeated injections into areas of cutaneous amyloidosis)

  • Hypoglycemia (with sudden change to unaffected injection site)

Decreased insulin requirements: Diarrhea, nausea/vomiting, malabsorption, hypothyroidism, renal impairment, and hepatic impairment; monitor therapy closely

Increased insulin requirements: Fever, hyperthyroidism, trauma, infection, and surgery

Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia; these changes should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased.

All insulin products can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia; untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia and death; monitor potassium levels in patients at risk for hypokalemia if indicated (eg, patients using potassium-lowering medications, patients taking medications sensitive to potassium concentrations)

Thiazolidinediones are peroxisome proliferator-activated receptor (PPAR)-gamma agonists and can cause dose-related fluid retention, particularly when used in combination with insulin; fluid retention may lead to or exacerbate heart failure; monitor for signs and symptoms of heart failure, treat accordingly, and consider discontinuing thiazolidinediones

Never share pen between patients even if needle is changed; patients using vials must never share needles or syringes with another person

To avoid accidental mix-ups between insulin products, instruct patients to always check insulin label before each injection

If hypersensitivity reactions occur, discontinue therapy; treat per standard of care and monitor until symptoms and signs resolve

Available information from published randomized controlled trials during second trimester of pregnancy have not reported association with insulin aspart and major birth defects or adverse maternal or fetal outcomes

There are no data on presence of insulin in human milk, effects on breastfed infant, or on milk production

Specific maximum dosage information is not available. Individualize dosage based on careful monitoring of blood glucose and other clinical parameters in all patient populations.

Insulin Aspart rDNA Origin

injectable solution

  • 100 units/mL (NovoLog, Fiasp)

prefilled syringe

  • 100units/mL (3mL NovoLog FlexPen, NovoLog FlexTouch, Fiasp FlexTouch)
DrugsAce
Logo